| 000 | 01804 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513235827.0 | ||
| 264 | 0 | _c20010712 | |
| 008 | 200107s 0 0 eng d | ||
| 022 | _a0953-816X | ||
| 024 | 7 |
_a10.1046/j.0953-816x.2001.01534.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKirik, D | |
| 245 | 0 | 0 |
_aDelayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. _h[electronic resource] |
| 260 |
_bThe European journal of neuroscience _cApr 2001 |
||
| 300 |
_a1589-99 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAmphetamine _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCorpus Striatum _xenzymology |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGlial Cell Line-Derived Neurotrophic Factor |
| 650 | 0 | 4 | _aInfusion Pumps |
| 650 | 0 | 4 | _aInjections, Intraventricular |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aNerve Degeneration _xchemically induced |
| 650 | 0 | 4 | _aNerve Growth Factors |
| 650 | 0 | 4 |
_aNerve Tissue Proteins _xpharmacology |
| 650 | 0 | 4 | _aOxidopamine |
| 650 | 0 | 4 |
_aParkinson Disease _xpathology |
| 650 | 0 | 4 |
_aParkinson Disease, Secondary _xchemically induced |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aRotation |
| 650 | 0 | 4 |
_aStereotyped Behavior _xphysiology |
| 650 | 0 | 4 |
_aSubstantia Nigra _xdrug effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 700 | 1 | _aGeorgievska, B | |
| 700 | 1 | _aRosenblad, C | |
| 700 | 1 | _aBjörklund, A | |
| 773 | 0 |
_tThe European journal of neuroscience _gvol. 13 _gno. 8 _gp. 1589-99 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.0953-816x.2001.01534.x _zAvailable from publisher's website |
| 999 |
_c11262250 _d11262250 |
||